Skip to content
Clinical Trials – home
PolandBack to Poland

Clinical trials in Tychy – page 16

1 211 clinical trials in Tychy, Poland across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

PolandOur site in PolandBadaniaKliniczne.pl(opens in a new tab)
Tychy at a glance
1 211
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

1 211 trials in Tychy

Open in trial search

Pharmacokinetics and safety of subcutaneous vs intravenous human normal immunoglobulin in adults with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP)

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Human Normal Immunoglobulin
  • Sponsor:Grifols Therapeutics LLC

Efficacy and safety of lunsekimig in adults with inadequately controlled eosinophilic COPD: a randomized, double‑blind, placebo‑controlled trial

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Lunsekimig
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Phase 3 Study Comparing JNJ-79635322 with Teclistamab in Patients with Relapsed or Refractory Multiple Myeloma after 1‑3 Prior Treatments

InvestigationalNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:JNJ-79635322
  • Sponsor:Janssen Cilag International

Rinatabart Sesutecan plus bevacizumab vs standard care as maintenance for recurrent platinum‑sensitive ovarian cancer after second‑line chemotherapy

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Genmab A/S

Phase 3 Study of Enpatoran in Patients with Active Cutaneous Lupus Erythematosus (with or without Systemic Disease)

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Enpatoran hemihydrate
  • Sponsor:Merck Healthcare KGaA

Study of MK-1084 plus durvalumab versus placebo plus durvalumab in patients with locally advanced KRAS G12C‑mutant non‑small cell lung cancer after chemoradiotherapy

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Merck Sharp & Dohme LLC

Colitis ulcerative+2

Recruiting

Study of ly4395089 and mirikizumab in adults with moderately to severely active Crohn’s disease

InvestigationalNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:LY4395089
  • Sponsor:Eli Lilly & Co.

Randomized Study of Intravitreal mk-8748 Compared with Aflibercept in Patients with Neovascular Age‑Related Macular Degeneration

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Aflibercept
  • Sponsor:Eyebiotech Limited

Phase 3 Study of Orelabrutinib with Rituximab and Bendamustine vs. Rituximab and Bendamustine in Treatment‑Naïve Mantle Cell Lymphoma Patients

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Orelabrutinib
  • Sponsor:Innocare Pharma Inc.

Study of nivolumab plus drug combination versus standard first-line therapy in patients with advanced Hodgkin lymphoma

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Brentuximab Vedotin
  • Sponsor:Polska Grupa Badawcza Chloniakow

Myelofibrosis+1

Recruiting

Study of pelabresib (DAK539) plus ruxolitinib versus placebo plus ruxolitinib in adult patients with myelofibrosis who are JAK‑inhibitor‑naive

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Ruxolitinib
  • Sponsor:Novartis Pharma AG

Study of MK-1045 alone or with tocilizumab in patients with Non‑Hodgkin Lymphoma to evaluate safety and efficacy

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:MK-1045
  • Sponsor:Merck Sharp & Dohme LLC

Other cities in Poland

The busiest research cities in the country

All 236 cities in Poland

Clinical research in Tychy

What the registry says about research in the country

01 Gastrointestinal Research

Comprehensive studies focusing on inflammatory bowel diseases, including multiple trials investigating new treatments for Crohn's Disease and Ulcerative Colitis. Research aims at evaluating novel therapeutic approaches for both moderate and severe cases.

  • Crohn's Disease Management
  • Ulcerative Colitis Treatments
  • Eosinophilic Esophagitis Studies

Clinical investigations are examining both established and experimental medications to improve patient outcomes and quality of life.

02 Cardiovascular Studies

Extensive research into heart conditions and related disorders, with particular focus on heart failure, myocardial infarction, and hypertension management. Studies evaluate both new medications and innovative treatment approaches.

  • Heart Failure Therapies
  • Post-Heart Attack Treatment
  • Blood Pressure Management

Trials are investigating both preventive measures and therapeutic interventions for various cardiovascular conditions.

03 Respiratory Research

Innovative studies focusing on respiratory infections and preventive treatments, particularly in vulnerable populations. Research includes evaluation of new preventive therapies for RSV in infants.

  • RSV Prevention
  • Respiratory Infection Management
  • Pediatric Respiratory Care

Clinical trials aim to develop effective preventive measures and treatments for respiratory conditions.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.